Fireside Chat, Interview, Conference Presentation, Panel
a16z Podcast | Scaling Healthcare
- Preventable chronic disease is projected to surpass infectious disease as the leading global cause of death, with diabetes-specific costs expected to inflate at a rate of approximately 5% year-over-year.
- A demographic trajectory where 40% of adults develop type two diabetes poses a risk to the U.S. economy's ability to sustain current disease trajectories.
- The threshold for employers to transition to self-insurance is expected to decline annually, driving a strategic shift from cost reduction alone to achieving better clinical outcomes.
- Digital therapeutics and personalized interventions are forecast to generate initial cost savings of 5% to 7% in the first year, with savings projected to increase in subsequent years as long-term consumer relationships are established.
- Omada Health intends to publish research proving the clinical efficacy of early metabolic disease intervention and will file claims through self-insured plans to facilitate discussions with benefits leaders.
- Self-insured employers are expected to utilize one-year claims data to demonstrate savings, while Omada Health plans to leverage 24 million structured weight readings to continuously personalize programs based on input, behavior, demographics, and clinical status.
- Accolade plans to measure performance via consumer engagement levels and ecosystem activation, assuming risk on specific population segments selected by clients to drive savings.
- Clinical trial outcomes for safety net Medicaid programs are expected to remain comparable to business-as-usual benchmarks.